 |
|
|
|
|
|
|
|
|
|
|
|
1 to 30 of 30 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Schmidt B. on NEWS: Dyeing Worms for an Extra-Long, Healthy Lifespan?, The remarkable life-extending activity of the high curcumin concentrations requires additional... 5 Apr 2011.
|
|
|
 |
|
|
Schmidt B. on PAPER: Ladiwala AR. et al., 2010, Resveratrol was reported in 8,000 publications and 7,332 biological studies so far. Most cases... 14 Jun 2010.
|
|
|
|
|
|
Schmidt B. on PAPER: Beel AJ. et al., 2009, This is one of the most interesting papers on γ-secretase modulation I have seen in a while.... 30 Nov 2009.
|
|
|
|
|
|
Schmidt B. on PAPER: Shelton CC. et al., 2009, This is an interesting paper. The lead structure, hydroxycoumarin, is rapidly accessible and... 20 Nov 2009.
|
|
|
|
|
|
Schmidt B. on PAPER: Abdul-Hay SO. et al., 2009, The results are noteworthy. However, how do these findings relate to the activity of γ-secretase... 17 Sep 2009.
|
|
|
|
|
|
Schmidt B. on PAPER: Perez M. et al., 2009, Recommendation Only. 4 Jun 2009.
|
|
|
|
|
|
Schmidt B. on PAPER: Saitoh M. et al., 2009, Although these inhibitors bind to the ATP site, the novel structural moiety displays impressing... 27 Feb 2009.
|
|
|
|
|
|
Schmidt B. on PAPER: Cole DC. et al., 2009, Recommendation Only. 13 Jan 2009.
|
|
|
|
|
|
Schmidt B. on PAPER: Mayer SC. et al., 2008, Recommendation Only. 28 Nov 2008.
|
|
|
|
|
|
Schmidt B. on NEWS: Chicago: Out of the Blue—A Tau-based Treatment for AD?, Is methylene blue, a rather old drug, finally on the way to becoming a cure? Speculation and... 26 Aug 2008.
|
|
|
|
|
|
Schmidt B. on PAPER: Jacobsen JS. et al., 2008, The Aβ lowering in vivo activity may be due to the very high structural analogy of PAZ-417 to... 22 Aug 2008.
|
|
|
|
|
|
Schmidt B. on PAPER: Ehrnhoefer DE. et al., 2008, This is interesting news for EGCG indeed. The authors already mention the caveats: poor oral... 7 Jun 2008.
|
|
|
|
|
|
Schmidt B. on PAPER: Barnham KJ. et al., 2008, This is novel and interesting work; however, it raises questions concerning approved AD targets... 13 May 2008.
|
|
|
|
|
|
Schmidt B. on PAPER: Voigt B. et al., 2008, Recommendation Only. 26 Nov 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Page RM. et al., 2008, Recommendation Only. 26 Nov 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Wang J. et al., 2007, The analysis of the pleitropic effects of Valsartan is striking. The potential of a class effect... 8 Nov 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Lefterov I. et al., 2007, Riddell et al. reported that TO-901317, a liver X receptor (LXR) agonist, at brain... 1 Nov 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Stains CI. et al., 2007, Recommendation Only. 1 Nov 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Imbimbo BP. et al., 2007, Recommendation Only. 1 Oct 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Stanton MG. et al., 2007, Recommendation Only. 23 Aug 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Rajapakse HA. et al., 2006, Recommendation Only. 23 Aug 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Baxter EW. et al., 2007, Recommendation Only. 23 Aug 2007.
|
|
|
|
|
|
Schmidt B. on LIVE DISCUSSION: Presenilin Loss of Function—Plan B for AD?, Shen and Kelleher's PNAS paper raises interesting questions, and it compiles data in favor of... 2 Feb 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Clarke EE. et al., 2006, Finally, a very sound analysis provides a model to explain the strange pharmacology of... 2 Feb 2007.
|
|
|
|
|
|
Schmidt B. on PAPER: Lanz TA. et al., 2006, LY-450139 did not have an easy start. There was always the issue of Notch selectivity. One... 14 Sep 2006.
|
|
|
|
|
|
Schmidt B. on PAPER: Ehrnhoefer DE. et al., 2006, EGCG is a frequent hitter in HTS, like many catechols. It was reported to inhibit BACE and the... 5 Sep 2006.
|
|
|
|
|
|
Schmidt B. on PAPER: Kokkoni N. et al., 2006, There have been many reports of peptide sequences as anti-amyloidgenic agents; so far all of... 17 Aug 2006.
|
|
|
|
|
|
Schmidt B. on PAPER: Kwak JW. et al., 2006, The work is sound, yet the title of the paper gives a bad taste to it. The potency of the most... 17 Aug 2006.
|
|
|
|
|
|
Schmidt B. on PAPER: Lazarov VK. et al., 2006, This is a very daring structural proposal, which will stimulate and spark many discussions. The... 1 May 2006.
|
|
|
|
|
|
Schmidt B. on PAPER: Siemers ER. et al., 2006, Finally, LY450139 progressed into phase Ib/IIa human trials despite the red flag associated with... 10 Mar 2006.
|
|
|
|
|
|
|
1 to 30 of 30 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
